eli lilly retatrutide trial A Study of (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Why Eli Lilly's Next-Gen Obesity

Among the current options, Wegovy can help people lose an average of 10 percent of their body weight in a year, while people taking Zepbound have had about a 15 percent loss, on average, in the same period

Refrigerator space for reconstituted peptides (separate from food for organization and safety)

Bone health is also a concern, especially for women in menopause who are already at risk for bone loss

Mood is better

3 min read The popularity of GLP-1s has skyrocketed in recent years, and a November 26 proposal from President Joe Bidens administration to allow Medicare and Medicaid to cover the medications could make them even more prominent